IL22 and colorectal carcinoma: In agreement with the deleterious effect of IL-22 in CRC, the sensing of microbial ligands by DCs downregulates IL-22BP expression, an antagonist of IL-22, and this downregulation increases inflammation and tumorigenesis in colitis-associated colon cancer models [58].